The world’s first smart needle is the result of more than 15 years of R&D

Imagine if doctors had a needle that could precisely identify when the tip reaches the right spot? That is the vision that sparked Injeq’s groundbreaking development work, the result of which is the first smart needle of its kind in the world.

The smart needle has been developed since 2003 by Injeq’s interdisciplinary team that combines solid medical and technological expertise. Katja Paassilta (DDS, MSc Eng), Riitta Seppänen-Kaijansinkko (MD, DDS, PhD, Prof) and Jari Hyttinen (DSc Tech, Prof), along with their teams, have carried out pioneering work to develop the bioimpedance-based measurement technology.

The very first prototype of the device was made using a commercial hypodermic needle and components purchased from an electronics store. Paassilta performed the first test punctures in her home, on gel tissue she made from gelatin.

Now, two decades later, the smart needle and the measurement unit connected to it include advanced technology and a unique measurement method in which the sensors and the entire measurement configuration are located in the tip of the needle.

The electrodes on the tip release a small electric current to the tissue surrounding the tip. The device, which precisely measures the tissue’s electrical conductivity at several different frequencies, identifies when the tip of the needle is exactly at the right puncture point. The device then sends an audio alert to the physician.

The measurement device can also be used in clinical studies and in teaching situations to collect data generated by the needle, thus enabling the entire puncture procedure to be analyzed in retrospect.

The first application of Injeq’s smart needle to be commercialized was developed in collaboration with oncologists and pediatricians particularly for the treatment of childhood leukemia. During the treatment of leukemia, dozens of lumbar punctures (spinal taps) are performed on the patient in order to take cerebrospinal fluid samples and to inject chemotherapy drugs into the spinal canal to kill cancer cells.

Injeq’s smart needle is currently being tested on leukemia patients in three central university hospitals in Finland. The clinical study, which has already seen more than 140 punctures performed in clinical tests, has been proceeding well.

Medicine has advanced in leaps and bounds over the past 100 years, but the needles used for performing punctures have evolved very little during that time. Injeq is finally bringing needles and the safety of punctures into this millennium.

We are excited to join the biggest German neurology event Neurowoche 2022

We are excited to join the biggest annual German neurology event Neurowoche 2022 with our distributor Ecumed. The congress takes […]
Read more »

Injeq participating Italian Neonatology congress SIN

Injeq is happy to join our Italian distributor Euromed at SIN – XXVIII Italian Neonatology Congress in beautiful Firenze. Come […]
Read more »

Injeq participating SIOP 2022 in Barcelona 28th September -1st October

Injeq is very excited to attend the SIOP Congress to present our amazing IQ-Tip system to doctors, patients and their […]
Read more »

Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population-based cohort study

An interesting article from Sørensen et al. about long term survival from childhood ALL (acute lymphoblastic leukemia). According to this […]
Read more »

German reseller Florian Holderer was dazzled by the smart needle

Ecumed’s CEO Florian Holderer emphasizes the importance of user experience and trust in the marketing of the IQ-Tip®​ smart needle. Florian Holderer […]
Read more »

Changes to the Injeq Plc. Board

The Annual General Meeting held on May 31 2022 made the regular decisions as defined in the by-laws. The new […]
Read more »